Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 7Thoracic 3Gastrointestinal 2Breast 2Genitourinary 1Dermatologic 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Mesothelioma 2Melanoma 2Cholangiocarcinoma 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 59Nivolumab 19atezolizumab 8Ipilimumab 8Docetaxel 7avelumab 6Paclitaxel 6cemiplimab 5Specimen Handling 5Cyclophosphamide 5Biopsy 5Taxes 4Pemetrexed 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Gemcitabine 4Carboplatin 4utomilumab 3epacadostat 3durvalumab 3Radiotherapy 3Cisplatin 3Cetuximab 3tremelimumab 2tislelizumab 2sargramostim 2poly ICLC 2obinutuzumab 2fludarabine 2enzalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × budigalimab × Dermatologic × Clear all
NCT02988960 2026-01-09

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
163 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡